Status:
COMPLETED
Subclass of Donor-specific Antibody as a Risk Factor of Antibody Mediated Rejection in Renal Transplantation
Lead Sponsor:
University Hospital, Montpellier
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Antibody-mediated Rejection
Eligibility:
All Genders
18+ years
Brief Summary
Antibody-mediated rejection is now recognized as the first cause of long-term kidney transplant loss. This type of rejection is mediated by the presence of graft-specific antibodies, usually directed ...
Detailed Description
Antibody-mediated rejection is now recognized as the first cause of long-term kidney transplant loss. This type of rejection is mediated by the presence of graft-specific antibodies, usually directed ...
Eligibility Criteria
Inclusion
- \- Patients over 18 years old
- Renal transplant patients followed at the University Hospital of Montpellier presenting a DSA de novo during follow-up.
- Affiliation or beneficiary of a social security scheme.
- Inclusion criteria specific to patients whose graft biopsy has already been performed
- Patients who consented to the collection of a plasma sample on graft biopsy day and use in future programs (Collection DC-2014-2328)
- Collection of non-opposition to participate in the study
- Inclusion criteria specific to patients whose biopsy of the graft has not already been performed:
- Eligible for graft biopsy for humoral-mediated rejection (according to Banff 2015 classification) (Appendix 1)
- Collection of non-opposition to participate in the study
- Signature of informed consent to participate in the collection of a plasma sample on graft biopsy day and use in future programs (Collection DC-2014-2328)
Exclusion
- Pregnant or lactating women according to Article L1121 5 of the health public Code
- Vulnerable persons according to article L1121-6 of the health public Code
- Major persons placed under guardianship or curator
Key Trial Info
Start Date :
July 18 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04026087
Start Date
July 18 2019
End Date
February 15 2023
Last Update
February 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Lapeyronie
Montpellier, Hérault, France, 34090